CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 45 enrolled
Drug / intervention
Abemaciclib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02981940
NCT02981940Phase 2Active
CompareCT.gov

A Phase 0/2 Study of Abemaciclib in Recurrent Glioblastoma

Dana-Farber Cancer Institute·interventional·Posted Dec 5, 2016·Updated Sep 2, 2025

In Brief

A Phase 2 clinical trial evaluating Abemaciclib and Surgery for Glioblastoma. Active but no longer recruiting, targeting 45 participants across 7 sites.

Detailed Summary

This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 2ActiveOverdue
2017201820192020202120222023202420252026
First PostedDec 5, 2016
Enrollment StartFeb 9, 2017
Primary CompletionJun 30, 2024
Study CompletionJun 30, 2026
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 9.6 years ago

Interventions

Abemaciclibdrug

Abemaciclib capsule

Surgeryprocedure

Surgery